Impact of PBP4 Alterations on β-Lactam Resistance and Ceftobiprole Non-Susceptibility Among Enterococcus faecalis Clinical Isolates.

Penicillin-resistance among Enterococcus faecalis clinical isolates has been recently associated with overexpression or aminoacidic substitutions in low-affinity PBP4. Ceftobiprole (BPR), a new-generation cephalosporin, is a therapeutic option against E. faecalis. Here, we present evidence that pbp4 gene sequence alterations may influence the expression level of the gene and ceftobiprole binding to PBP4 in E. faecalis clinical isolates showing remarkable MDR-phenotypes, and how this could interfere with BPR in vitro antibacterial and bactericidal activity. Seven E. faecalis strains from bloodstream infections were analyzed for their antibiotic and β-lactam resistance. BPR bactericidal activity was assessed by time-kill analysis; pbp4 genes were sequenced and pbp4 relative expression levels of transcription were performed by RT-qPCR. Five penicillin-resistant ampicillin-susceptible (PRAS) isolates were detected, 4 of which were also BPR non-susceptible (BPR-NS). In the time-kill experiments, BPR exposure resulted in a potent bactericidal activity (3-5 log10 reduction) at the different concentrations tested. pbp4 gene sequence analysis revealed some mutations that may account for the changes in PBP4 affinity and MIC increase in the 4 BPR-NS strains (MICs 4-16 mg/L): the deletion of an adenine (delA) in the promoter region in all PRAS/BPR-NS strains; 12 different amino acid substitutions, 7 of which were next to the PBP catalytic-sites. The most significant were: T418A, located 6 amino acids (aa) upstream of the catalytic-serine included in the 424STFK427 motif I; L475Q, 7 aa upstream of the 482SDN484 motif II; V606A and the novel Y605H, 13/14 aa upstream of the 619KTGT622 motif III. Taken together, our data showed that elevated BPR MICs were attributable to increased transcription of pbp4 - associated with a single upstream adenine deletion and PBP4 alterations in the catalytic-site motifs - which might interfere with the formation of the BPR/PBP4 complex. pbp4 molecular alterations may account for the changes in PBP4 affinity and MIC increase, without affecting BPR cidal activity. Indeed, our in vitro dynamic analysis by time-kill assays showed that BPR exerted a bactericidal activity against E. faecalis clinical isolates, despite their MDR phenotypes.

Introduction

Enterococci are the third most commonly isolated nosocomial pathogens, accounting for 12% of all hospital infections (Hollenbeck and Rice, 2012). The clinical importance of the genus Enterococcus is closely related to antibiotic resistance, which contributes to the risk of infection.

Enterococci have high-level resistance to most cephalosporins and all semi-synthetic penicillins.

Among the species of greatest clinical interest, E. faecalis is intrinsically resistant to most β-lactams and only susceptible to a limited group of penicillins, such as ampicillin, penicillin and piperacillin (Arias and Murray, 2012; Kristich et al., 2014a).

Ampicillin resistance has been rarely reported in E. faecalis, as this did not represent a clinical and therapeutic challenge. Until recently, it was assumed that ampicillin- susceptible E. faecalis was also susceptible to penicillin, but E. faecalis clinical isolates have been exhibiting increasing levels of resistance to penicillin, due to the emergence of Penicillin-Resistant Ampicillin-Susceptible (PRAS) isolates, eliminating β-lactams as a treatment option. This uncommon phenotype has been reported in various hospitals worldwide but its real epidemiological impact is still unknown (Metzidie et al., 2006; Guardabassi et al., 2010; Tan et al., 2014; Cabrera et al., 2020; Conceição et al., 2020; Gawryszewska et al., 2021).

Reduced susceptibility to β-lactams in E. faecalis is attributable to two main mechanisms: the first is the production of β-lactamases, rarely described among E. faecalis strains (Rice and Murray, 1995; Sarti et al., 2012; Schell et al., 2020), while the second is the over-production of a single low-affinity class B penicillin-binding protein (PBP), named PBP4. The PBP4 active site in the Trans-Peptidase (TPase) domain encompasses three conserved motifs: the 424STFK427 motif I, containing the catalytic serine; the 482SDN484 motif II, involved in the protonation of the β-lactam leaving group; and the 619KTGT622 motif III, which facilitates substrate binding and defines the oxyanion hole (Ghuysen, 1991; Djorić et al., 2020). Accumulation of point mutations in the penicillin-binding module of PBP4 has been associated with a decreased affinity for β-lactams (Ono et al., 2005; Zapun et al., 2008; Infante et al., 2016; Moon et al., 2018; Rice et al., 2018; Gawryszewska et al., 2021).

The pandemic led to an alarming increase of E. faecalis isolated from patients with COVID-19 under mechanical ventilation and ICU-acquired enterococcals BSI (Giacobbe et al., 2021; Posteraro et al., 2021), also worsened by their increasing multi-resistance to all therapeutic options. E. faecalis pathogens play a crucial role in determining the severity of the clinical conditions, critically influencing the patients’ outcome, and represent a serious threat in infection therapy (Kim et al., 2019).

Among 5th generation cephalosporins, ceftobiprole exerts superior in vitro antibacterial and bactericidal activity also against vancomycin-resistant and β-lactamase producing strains, due to its high affinity for PBPs (Mendes et al., 2016; Hamilton et al., 2017; Campanile et al., 2019).

The aims of this study were: 1) to investigate the in vitro antibacterial and bactericidal activity of BPR alone against E. faecalis clinical isolates belonging to selected antibiotic-resistance classes; 2) to analyze the occurrence of pbp4 mutations and verify their role in influencing the activity of β-lactams and, specifically, of BPR; 3) to compare the pbp4 expression levels in all E. faecalis clinical isolates with reduced susceptibility to beta-lactams and PBP4 alterations, with the aim of evaluating which of these alterations may be involved in non-susceptibility and BPR cidal activity, and how.

Materials and Methods

Strains

Seven E. faecalis clinical strains, isolated from bloodstream infections (BSI) in Italian hospitals, were selected for their antibiotic-resistance behaviors from a larger collection of twenty-two isolates already characterized (Campanile, et al. 31st ECCMID 2021, P 2004). They belonged to the major MDR phenotypes (PRAS, BPR-NS, VRE, HLAR); two beta-lactam-susceptible E. faecalis isolates were also selected for comparison.

E. faecalis OG1RF, deposited in the American Type Culture Collection (ATCC) under ATCC 47077, deriving from E. faecalis OG1 by selection for resistance to rifampin and fusidic acid (Bourgogne et al., 2008), was used as control in molecular studies. E. faecalis ATCC 29212 was used as control for antibiotic-susceptibility tests (EUCAST, 2021).

Antimicrobial Susceptibility Testing

Ceftobiprole was provided by Basilea Pharmaceutica International Ltd. (Basel, Switzerland); ceftaroline, linezolid and tigecycline by Pfizer Inc. (New York, NY, USA); daptomycin by Novartis (Basel, Switzerland). Penicillin, ampicillin, amoxicillin, imipenem, vancomycin, teicoplanin, gentamicin and streptomycin were purchased commercially (Sigma Chemical Co., ST. Louis, MO, USA). MICs were determined by broth microdilution and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints (http://www.eucast.org/clinical_breakpoints/) (EUCAST, 2021). In the absence of EUCAST clinical breakpoints, those of the Clinical and Laboratory Standards Institute were applied (Clinical and Laboratory Standards Institute, 2021).

Bactericidal Assays

In vitro time-kill experiments were performed in duplicate in 20 mL tubes containing Cation Adjusted Mueller-Hinton broth (CA-MHB) (Difco, Detroit, MI) using a starting inoculum of 105-106 CFU/mL with ceftobiprole (1X, 2X and 4X MIC). Bactericidal activity was defined as a ≥3 log10 decrease in bacterial count at 24h (White et al., 1996). Statistical analysis was performed using GraphPad Prism (Version 8.4.0). All experiments were performed in triplicate. Data were represented as mean ±SD of triplicate experiments.

Gene Amplification and Sequence Analysis

All isolates were molecularly characterized for the pbp4 gene sequence in order to analyze possible mutations and verify their role in influencing BPR activity. pbp4 was amplified by PCR and the entire gene was double-strand sequenced using oligonucleotides specifically designed for this study ( ). Sequencing was performed using the Dye Terminator DNA sequencing kit V1.1 (Applied Biosystems TM), followed by purification using the DyeEx 2.0 Spin Kit (Quiagen, Hilden, Germany). The sequences obtained were corrected and analyzed using the Chromas Lite 2.1 program and then exported in FASTA format. Sequence alignment and gene and translated protein analysis were performed by using BLAST tool (Basic Local Alignment Search Tool) (https://blast.ncbi.nlm.nih.gov/Blast.cgi), CLC Sequence Viewer 8.0 and UniProt (www.uniprot.org). E. faecalis ATCC 47077, whose complete genome sequence is deposited at NCBI under the accession number CP025020.1., was used as reference.

Real-Time Quantitative PCR

For real-time quantitative PCR (RT-qPCR) studies, 7 mL of bacterial suspensions (105 CFU/mL) were incubated at 37°C until late-log-phase (0.1 OD600 ≅ 1x108 CFU/mL); total RNA was extracted using the RNeasy® Mini kit (Qiagen, Hilden, Germany), purified from contaminating DNA genomics and retro-transcripted in cDNA using the QuantiNova™ Reverse Transcription Kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. cDNA was quantified using the Qubit™ 4 fluorometer.

RT-qPCR was performed in a Rotor-Gene Q (Qiagen, Hilden, Germany) instrument, using the QuantiNova™ SYBR® Green PCR kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. pbp4 (5RT) and 16S rRNA qPCR oligonucleotides were specifically designed for this study ( ). For each sample, three biological replicates were prepared. Relative gene expression levels of transcription were calculated by the quantification cycle (Cq) method and normalized to the expression of 16S rRNA. Relative expression was calculated using the 2- ΔΔ Ct method (Livak and Schmittgen, 2001). The data obtained were expressed as the fold-change in expression compared to that of the ATCC 47077 reference. Comparison of the expression levels of transcription of all strains and statistical analysis were conducted using the Relative Expression Software Tool “REST 2009” (Qiagen, Hilden, Germany) and GraphPad Prism (Version 8.4.0).

Results

In Vitro Antibacterial Activity

shows the susceptibility values of the 7 E. faecalis strains in study to β-lactams and comparator drugs. Five strains were found to be penicillin-resistant ampicillin-susceptible (PRAS), besides showing reduced susceptibility to ceftaroline (MICs ≥4 mg/L). Four out of 5 strains showed higher ceftobiprole MIC values (≥4 mg/L) and were reported as ceftobiprole non-susceptible (BPR-NS). All isolates were also susceptible to the other β-lactams tested (amoxicillin and imipenem), and susceptible to daptomycin, linezolid and tigecycline. High-level resistance to gentamicin (HLGR) (n=1), streptomycin (HLSR) (n=1) and both aminoglycosides (HLAR) (n=4) was detected. Vancomycin and teicoplanin resistance (VRE) was detected in 2 isolates and further found to be associated with the presence of the vanA gene.

Table 1

Beta-lactams and comparator antimicrobial MIC values against E. faecalis clinical isolates.

Code	MIC values (mg/L)
	P1	AMP	AML	IMI	BPR2	CPT2	VA	TEC	CN	S	LNZ	TGC	DAP1
Efs1	16	1	0.5	4	16	>256	0.5	2	>1024	>1024	4	0.25	0.5
Efs2	4	0.5	0.5	4	2	1	4	2	32	256	4	0.125	0.5
Efs7	64	4	4	4	8	>256	1	2	>1024	>1024	4	0.06	0.5
Efs8	16	4	1	2	4	32	>256	>256	>1024	128	4	0.125	0.5
Efs11	16	4	1	4	2	32	>256	128	>1024	>1024	2	0.25	0.5
Efs18	16	2	1	2	4	4	1	2	>2048	>1024	2	0.125	0.5
Efs20	4	2	0.5	1	0.25	0.5	1	0.5	32	>1024	2	0.06	1

1Penicillin and Daptomycin susceptibility values were established according to CLSI breakpoints (EUCAST breakpoints absent). 2Ceftobiprole and Ceftaroline: No EUCAST and CLSI official breakpoints; eCOFFs not determined.

P, Penicillin; AMP, Ampicillin; AML, Amoxicillin; IMI, Imipenem; BPR, Ceftobiprole; CPT, Ceftaroline; VA, Vancomycin; TEC, Teicoplanin; CN, Gentamicin; S, Streptomycin; LNZ, Linezolid; TGC, Tigecyclin; DAP, Daptomycin.

Bactericidal Activity of Ceftobiprole

In BPR-NS, BPR exposure resulted in a potent bactericidal activity (3 to 5 log10) at 4X MIC after 24h. BPR-S strains showed a greater log reduction (3 to 5 log10) even at lower concentrations (i.e., 1X and/or 2X MIC). Enhanced killing activity was also observed at 8 h ( ).

Figure 1

Time-kill assays of ceftobiprole (BPR) against the seven E. faecalis clinical isolates in study. Cell count was reported as log10 (CFU/ml) at 0, 2, 4, 8 and 24h Time-points (T0, T2, T4, T24); Ceftobiprole (BPR) exposure was tested at 1X, 2X and 4X MICs. Error bars represent standard deviations (±SD) of the mean of triplicate experiments (A–G).

pbp4 Sequence Analysis and Significant Protein Alterations

PCR and sequence analysis of the pbp4 gene revealed some mutations that may account for the changes in PBP4 affinity and MIC increase in the 4 BPR-NS strains (MICs 4-16 mg/L). The adenine deletion (delA) in the promoter region, 8bp upstream of the -35 consensus site, was the carried by all 4 strains showing non-susceptibility to BPR and high-level resistance to penicillin ( , ). Sequence analysis of translated PBP4 identified 12 different missense mutations, 7 of which were next to the PBP catalytic sites ( ; ). Notably, the T418A mutation (Efs1) was located 6 amino acids (aa) upstream of the catalytic serine included in the 424STFK427 motif I; L475Q (Efs8), 7 aa upstream of the 482SDN484 motif II, involved in β-lactam leaving group protonation; the novel Y605H (Efs18) and V606A (Efs7), 13/14 aa upstream of the 619KTGT622 motif III, which facilitates substrate binding. Other mutations were found far from the PBP catalytic site: i) T50I, quite common in our sample (3/7), and I223V, only present in a fully susceptible strain (Efs20) in which it does not affect MICs to β-lactams, both located in the N-terminal end; ii) L639F, T665I and T678A (all in Efs7), and D666P (Efs1), located in the C-terminal end.

Table 2

Ceftobiprole MIC values (mg/L) and expression levels for E. faecalis clinical isolates, compared to sequence alterations.

Code	Phenotype characteristics	BPR MIC (mg/L) a	§Fold-change mean	Deletion in promoter regionb	Amino acid substitutions in PBP4d
							PBP active-sites
					50T	223I	418T	475L	536A	573D	605Y	606V	639L	665T	666D	678T
Efs20	PSAS; BPR-S; HLSR	0.25	88. 80	–	-	V	-	-	-	-	-	-	-	-	-	-
Efs2	PSAS; BPR-S; fully susceptible	2	77.36	–	-	-	-	-	-	-	-	-	-	-	-	-
Efs11	PRAS; BPR-S; VRE/vanA; HLAR	2	695.413	–	-	-	-	-	-	E	-	-	-	-	-	-
Efs8	PRAS; BPR-NS; VRE/vanA; HLGR	4	4851.96	2013028_2013029 delA c	I	-	-	Q	-	-	-	-	-	-	-	-
Efs18	PRAS; BPR-NS; HLAR	4	422.88	2013028_2013029 delA c	-	-	-	-	-	-	H	-	-	-	-	-
Efs7	PRAS; BPR-NS; HLAR	8	571.068	2013028_2013029 delA c	I	-	-	-	-	-	-	A	F	I	-	A
Efs1	PRAS; BPR-NS; HLAR	16	698.895	2013028_2013029 delA c	I	-	A	-	T	-	-	-	-	-	P	-

aBPR, Ceftobiprole; ba single base pair deletion 8 bases upstream of the putative -35 region; cAccession number GenBank: CP025020.1 (ATCC47077); dProtein ID GenBank: AEA94594.1 (ATCC47077); §Fold-change expression levels relative to that of ATCC47077. Average of three independent experiments. HLSR, High Level Streptomycin Resistance; VRE, Vancomycin Resistant E. faecalis; HLAR, High Level Aminoglycosides Resistance; PRAS, Penicillin-Resistant Ampicillin-Susceptible; BPR-NS, Ceftobiprole Non-Susceptible; PSAS, Penicillin-Susceptible Ampicillin-Susceptible; BPR-S, Ceftobiprole Susceptible; HLGR, High Level Gentamicin Resistance. GenBank accession no. from OM032878 to OM032884.

Figure 2

Amino acid substitutions and domain architecture of PBP4 of E faecalis clinical isolates. GenBank accession no. from OM032878 to OM032884. The numbers above the diagrams indicate residue numbers of the domain boundaries in the proteins. (A) Non-Penicillin Binding module (nPB); Penicillin Binding module (PB); TM, transmembrane helix region. 424STFK427, 482SDN484 and 619KTGT622: catalytic-site motifs (STFK424 includes the catalytic serine S424). (B) The domain architecture of PBP4 of E faecalis ATCC 47077 (OG1RF) was analyzed using SMART (Simple Modular Architecture Research Tool; http://smart.embl-heidelberg.de/) and reported in a simplified version.

Two further mutations in the region between the 482SDN484 and 619KTGT622 catalytic sites were detected (A536T; D573E) in Efs1 and Efs11, respectively; in Efs11, the D573E substitution potentially affects the MIC values of penicillin and ceftaroline (16 and 32 mg/L, respectively), but not those of ceftobiprole (2 mg/L).

Nucleotide Sequence Accession Numbers. The complete sequences of the pbp4 gene variants have been deposited in GenBank under accession numbers from OM032878 to OM032884.

Increase in the Level of pbp4 Expression

The evaluation of pbp4 gene expression relative to that of the ATCC47077 (OG1RF) reference strain showed varying levels of upregulation in all strains, linked to their β-lactam MIC values. The PRAS/BPR-S Efs2 and Efs20 strains exhibited lower expression levels (≤102 fold-change increase). All PRAS-BPR-NS strains carrying the delA in the pbp4 promotor region and mutations in the PBP catalytic sites displayed pbp4 overexpression with greater fold-change increases (0.5-4 x103).

We observed that pbp4 gene expression was more evident in the VRE/vanA strains (PRAS/BPR-NS Efs8 and PRSA/BPR-S Efs11), with or without delA in the promoter region ( , pattern-filled bars).

Figure 3

pbp4 gene expression analysis of the E. faecalis isolates in study, compared to that of the ATCC 47077 (OG1RF) reference. Evaluation of pbp4 relative mRNA expression expressed as fold-change (linear). 16S rRNA gene expression levels were used as calibrator. ATCC 47077 (OG1RF) was used as reference. Error bars indicate the average of three biological replicates in three RT-qPCR assays ± SD; PSAS, white; PRAS, gray. VRE/vanA, pattern-filled bars.

Correlation Between Sequence Alterations and Expression Level Increase

Missense mutations in the pbp4 sequence were common in BPR-NS and fully susceptible strains.

We observed a strong association between the increase in the level of pbp4 expression and the adenine deletion in the promoter region, upstream of the coding sequence. delA leads to a 3 log10 increase compared to that of the ATCC47077 (OG1RF) reference in all BPR-NS strains, demonstrating its role in establishing in vitro non-susceptibility to BPR, although it does not influence bactericidal activity ( ).

The only exception was Efs11 (PRAS; CPT-NS; BPR-S), carrying only the D573E substitution. We were not able to demonstrate whether this mutation within the SDN/KTG catalytic sites alone may potentially interfere with the expression of pbp4 transcription, or if the higher upregulation may be related to the VRE/vanA phenotype, as stated above. Further experiments are needed to confirm its role.

Discussion

High resistance to penicillins in E. faecalis strains is rare, it can emerge after prolonged β-lactam therapy treatments (Rice et al., 2018). Nevertheless, the PRAS phenotype was described in several countries (Metzidie et al., 2006; Guardabassi et al., 2010; Conceição et al., 2014), but its epidemiological and clinical impact remains ambiguous, as ampicillin is the treatment of choice for enterococcal infections (Kristich et al., 2014a) and penicillin MIC values were never reported (Mendes et al., 2016). Recently, Kim et al. reported significative differences in mortality rates in patients with a PRAS E. faecalis BSI, likely due to the treatment failures of ampicillin and/or piperacillin (Kim et al., 2019).

PBP4, like other PBPs of the same class B (i.e., PBP2a of methicillin-resistant S. aureus) performs the cross-linking reaction of the peptidoglycan (PG) biosynthesis, but retains low responsiveness to beta-lactams. Due to its low-reactivity, PBP4 is considered the key basis for intrinsic resistance to cephalosporins in E. faecalis (Arbeloa et al., 2004).

Ceftobiprole, a novel cephalosporin that inhibits the PG cross-linking reaction by acylating the active-site serine of PBPs, maintains a higher affinity for PBP4. Due to its unique ability to target low-affinity PBP4, ceftobiprole is the best candidate as a valid therapeutic option for remarkable E. faecalis MDR-phenotypes such as PRAS and VRE. Alterations in this enzyme cause conformational changes that impact the structure of the catalytic motifs (Moon et al., 2018).

This study addressed the mechanism of non-susceptibility to ceftobiprole and the resulting interactions with E. faecalis clinical strains, all isolated from bloodstream infections.

A link between benzyl-penicillin resistance and 5th generation cephalosporins non-susceptibility was observed. Our data suggest that this common insensitivity in PRAS isolates results from the involvement of pbp4 mutations in increased gene expression levels and alteration of the penicillin binding domain that could remodel the PBP/β-lactam complex.

Our in vitro dynamic data by time-kill curve assays showed that BPR exerts a bactericidal activity against E. faecalis isolates despite their MDR phenotypes (VRE, PRAS and BPR-NS), and PBP4 alterations, even after 8h, consistently with other studies (Werth and Abbott, 2015; Arias et al., 2007). After 24 hours, the bactericidal activity against all isolates - with or without significative PBP4 changes - was similar, suggesting that ceftobiprole maintains high affinity also for other PBPs.

The majority of the PBP4 mutations found in this study were already reported in the literature, frequently related to PRAS strains (Conceição et al., 2014; Infante et al., 2016; Gawryszewska et al., 2021), but the mechanisms underlying this relationship were not elucidated.

It is well known that the upstream region consensus sequence, in the bacterial promoters, can have an impact on the expression of downstream coding genes (Estrem et al., 1998). In E. faecalis, the involvement of an adenine deletion (delA) upstream of the -35 region of the pbp4 promoter was recently analyzed in a single strain (Rice et al., 2018). Supported by these observations, we provided a comprehensive analysis on a larger sample of clinical strains belonging to different antibiotic-resistance profiles.

In all BPR-NS, we observed that the delA upstream of the coding sequence results in pbp4 overexpression, hypothetically altering the binding of regulatory proteins. Elevated expression levels may cause increased transpeptidation, resulting in a highly cross-linked peptidoglycan. This demonstrates its role in establishing in vitro non-susceptibility to BPR without affecting its cidal activity.

The combination of delA with additional significant amino acid changes within the PBP4 active sites might result in destabilization and formation of a less competent β-lactam binding-complex. In one PRAS/BPR-NS strain (Efs1), the T418A mutation located 6 amino acids upstream of the catalytic serine included in the 424STFK427 motif I affects the MIC value of BPR (BPR 16 mg/L), which only remains bactericidal at the highest BPR concentration tested (4X MIC). On the contrary, the I223V mutation located in the N-terminal end, carried by a PSAS/BPR-S strain (Efs20), does not affect the MIC of β-lactams. This region is known to have no enzymatic function (Infante et al., 2016; Rice et al., 2018; Djorić et al., 2020), and this corroborates the excellent in vitro antibacterial and bactericidal activity of BPR against this strain, exerted at 1X, 2X and 4X MICs.

We observed that pbp4 was more overexpressed in the VRE/vanA strains regardless of delA in the promoter region (Efs8 and Efs11) ( , pattern-filled bars); these strains also reported lower BPR MIC values (2-4 mg/L). This phenomenon was difficult to explain. In VRE/vanA isolates, the DAla-DLac PG precursor is not processed by PBP4, as previously reported in E. faecium for PBP5 (al-Obeid et al., 1992). We could hypothesize that PBP4 may not work with the modified precursor ending in DLac as it may not be able to identify the target, and this may result in overexpression and subsequent buildup. Besides, production of precursors ending in DAla or in DLac alternatively responsible for resistance to cephalosporins or glycopeptides may promote enhanced cephalosporin susceptibility in the presence of vancomycin/beta-lactam association (Kristich et al., 2014b).

Even though the aim of this study was not to trace E. faecalis epidemiology, we detected three strains carrying PBP4 variants already reported in hospital-associated PRAS strains, epidemiologically related to the High-Risk Enterococcal Clonal Complex (HiRECC) CC87 (Kuch et al., 2012; Gawryszewska et al., 2021). In particular, Efs7 exhibited 4 combined mutations in PBP4 (designating the F3 variant), hypothetically responsible for its indifference to 1X MIC ceftobiprole concentration, in time-kill assays; Efs1, 3 combined mutations (E1 variant); and Efs8, a single mutation (C4 variant). This observation has a clinical and epidemiological impact: the evolution of nosocomial CCs is driven by the acquisition of resistance genes, and the spread of PBP4 variants, responsible for resistance to all beta-lactams, may potentially compromise the clinical efficacy of E. faecalis therapy in hospital settings.

In conclusion, in this study we revealed that benzyl-penicillin and 5th generation cephalosporins interact with PBP4 in similar ways. In PRAS/BPR-NS E. faecalis clinical isolates, the interaction between increased pbp4 gene expression, due to the delA in the upstream region consensus sequence, and the supposed remodeling of the penicillin-binding domain, due to alterations in the PBP4 amino acid sequence, influence their β-lactams susceptibility profiles without affecting BPR cidal activity.

In the light of the above, we recommend penicillin MICs determination not just for clinical, but also and foremost for epidemiological purposes, to evaluate the spread of isolates belonging this difficult-to-treat epidemic PRAS phenotype as well as to address the proper antimicrobial treatment options for these infections.

The major limitation of this study is the lack of a functional evaluation of delA and amino acid substitutions in PBP4. Further experimental approaches such as whole genome sequence analysis and site-directed mutagenesis, should be attempted to confirm the genetic basis of altered beta-lactams/PBP4 complexes induced by sequence substitutions.

Data Availability Statement

The data presented in the study are deposited in the GenBank repository (https://www.ncbi.nlm.nih.gov/genbank), under accession numbers from OM032878 to OM032884.

Author Contributions

FC designed the research and directed the project. LL, MC, and FC conducted the research. LL, MC and FC analyzed the data. LL, MC, SS, and FC wrote the manuscript. FC and SS, edited and reviewed the manuscript. All authors read and approved the manuscript.

Funding

This study was partially supported by ADVANZ PHARMA and Programma PIACERI [CovDock]-Linea di intervento 2’, University of Catania, Dept. of Biomedical and Biotechnological Sciences (BIOMETEC).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.